King Luther Capital Management Corp Has $6.39 Million Stock Position in Enovis Co. (NYSE:ENOV)

King Luther Capital Management Corp lowered its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 16.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,391 shares of the company's stock after selling 29,471 shares during the period. King Luther Capital Management Corp owned about 0.27% of Enovis worth $6,388,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Diamond Hill Capital Management Inc. boosted its position in Enovis by 7.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock valued at $129,352,000 after purchasing an additional 218,660 shares during the period. Royce & Associates LP lifted its stake in Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock valued at $103,479,000 after buying an additional 346,317 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Enovis by 78.6% during the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock valued at $68,337,000 after acquiring an additional 665,208 shares during the period. River Road Asset Management LLC bought a new position in shares of Enovis during the third quarter worth about $51,341,000. Finally, Magnetar Financial LLC increased its holdings in shares of Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock worth $49,937,000 after acquiring an additional 442,051 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Price Performance

Shares of ENOV traded up $0.49 during mid-day trading on Friday, hitting $46.66. The company's stock had a trading volume of 604,677 shares, compared to its average volume of 581,321. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of -21.13 and a beta of 1.91. The firm has a 50-day moving average price of $42.63 and a 200 day moving average price of $45.04. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company's revenue was up 21.0% compared to the same quarter last year. During the same period last year, the company posted $0.56 EPS. On average, research analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENOV. Evercore ISI dropped their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. JPMorgan Chase & Co. reduced their price target on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Needham & Company LLC restated a "buy" rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Finally, JMP Securities assumed coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Enovis presently has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.